Correlation analysis of SNRPD2 and SF3A3 expression against the expression of the 789 NJs across all glioma subtypes supported our hypothesis that decreased SNRPD2 and SF3A3 expression levels may contribute to greater NJ expression (Fig. 3k). The gene discussed is SNRPD2; the disease is central nervous system cancer.